Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Armata Pharmaceuticals Inc (ARMP)

Armata Pharmaceuticals Inc (ARMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,326
  • Shares Outstanding, K 36,145
  • Annual Sales, $ 4,470 K
  • Annual Income, $ -23,160 K
  • 60-Month Beta 0.64
  • Price/Sales 18.18
  • Price/Cash Flow N/A
  • Price/Book 1.78
Trade ARMP with:

Options Overview Details

View History
  • Implied Volatility 218.67% ( +67.89%)
  • Historical Volatility 95.47%
  • IV Percentile 98%
  • IV Rank 56.00%
  • IV High 390.27% on 11/25/22
  • IV Low 0.29% on 03/04/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1
  • Open Int (30-Day) 15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +15.14%
on 11/25/22
3.40 -37.35%
on 11/08/22
-0.76 (-26.42%)
since 11/04/22
3-Month
1.85 +15.14%
on 11/25/22
4.92 -56.71%
on 09/26/22
-1.90 (-47.15%)
since 09/02/22
52-Week
1.85 +15.14%
on 11/25/22
6.46 -67.03%
on 01/06/22
-2.37 (-52.67%)
since 12/03/21

Most Recent Stories

More News
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)

Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

ARMP : 2.13 (-5.33%)
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing

Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

ARMP : 2.13 (-5.33%)
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

ARMP : 2.13 (-5.33%)
PTN : 3.65 (-8.98%)
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.13 (-5.33%)
Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CLXT : 0.1633 (-6.10%)
ARMP : 2.13 (-5.33%)
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

ARMP : 2.13 (-5.33%)
XSPA : 0.6550 (-5.65%)
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.13 (-5.33%)
TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -33.33% and 1.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA : 8.60 (+2.63%)
ARMP : 2.13 (-5.33%)
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

RNA : 11.18 (-3.87%)
ARMP : 2.13 (-5.33%)
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -50% and 30.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

ARMP : 2.13 (-5.33%)
IONM : 0.4176 (+1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including...

See More

Key Turning Points

3rd Resistance Point 2.43
2nd Resistance Point 2.38
1st Resistance Point 2.31
Last Price 2.13
1st Support Level 2.19
2nd Support Level 2.14
3rd Support Level 2.07

See More

52-Week High 6.46
Fibonacci 61.8% 4.70
Fibonacci 50% 4.16
Fibonacci 38.2% 3.61
Last Price 2.13
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar